{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:52:22Z","timestamp":1792043542121,"version":"4.4.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Health","award":["027\/0089"],"award-info":[{"award-number":["027\/0089"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4108-y","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T10:39:40Z","timestamp":1561372780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK"],"prefix":"10.1186","volume":"19","author":[{"given":"Samik","family":"Datta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham F.","family":"Medley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Staniszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Sonnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt J.","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"issue":"5","key":"4108_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","volume":"102","author":"L Koutsky","year":"1997","unstructured":"Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997; 102(5):3\u20138.","journal-title":"Am J Med"},{"key":"4108_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jcv.2004.12.008","volume":"32","author":"JG Baseman","year":"2005","unstructured":"Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005; 32:16\u201324.","journal-title":"J Clin Virol"},{"issue":"31","key":"4108_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","volume":"2003","author":"FX Bosch","year":"2003","unstructured":"Bosch FX, De Sanjos\u00e9 S. Chapter 1: Human papillomavirus and cervical cancer\u2014burden and assessment of causality. JNCI Monogr. 2003; 2003(31):3\u201313.","journal-title":"JNCI Monogr"},{"issue":"6","key":"4108_CR4","first-page":"485","volume":"12","author":"H Richardson","year":"2003","unstructured":"Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutl\u00e9e F, Franco E. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomark Prev. 2003; 12(6):485\u201390.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4108_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcv.2004.10.021","volume":"32","author":"H-U Bernard","year":"2005","unstructured":"Bernard H-U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol. 2005; 32:1\u20136.","journal-title":"J Clin Virol"},{"issue":"1","key":"4108_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/virtualmentor.2012.14.1.msoc1-1201","volume":"14","author":"KA Intlekofer","year":"2012","unstructured":"Intlekofer KA, Cunningham MJ, Caplan AL. The HPV vaccine controversy. Virtual Mentor. 2012; 14(1):39.","journal-title":"Virtual Mentor"},{"key":"4108_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.vaccine.2005.09.054","volume":"24","author":"H Trottier","year":"2006","unstructured":"Trottier H, Franco E. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 24:4\u201315.","journal-title":"Vaccine"},{"issue":"1","key":"4108_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.bjc.6603501","volume":"96","author":"M Kohli","year":"2007","unstructured":"Kohli M, Ferko N, Martin A, Franco E, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus 16\/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer. 2007; 96(1):143\u201350.","journal-title":"Br J Cancer"},{"issue":"1","key":"4108_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","volume":"13","author":"M Lehtinen","year":"2012","unstructured":"Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagu\u00e9 X, Skinner SR, Apter D, Naud P, Salmer\u00f3n J, et al. Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13(1):89\u201399.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4108_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/infdis\/jit361","volume":"208","author":"R Howell-Jones","year":"2013","unstructured":"Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill O, Hughes G. Declining genital warts in young women in England associated with HPV 16\/18 vaccination: an ecological study. J Infect Dis. 2013; 208(9):1397\u2013403.","journal-title":"J Infect Dis"},{"key":"4108_CR11","volume-title":"Human Papillomavirus (HPV) vaccine coverage in England, 2008\/09 to 2013\/14: A review of the full six years of the three-dose schedule","author":"Public Health England","year":"2014","unstructured":"Public Health England. Human Papillomavirus (HPV) vaccine coverage in England, 2008\/09 to 2013\/14: A review of the full six years of the three-dose schedule. London: Public Health England; 2014."},{"issue":"24","key":"4108_CR12","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1016\/j.vaccine.2012.03.063","volume":"30","author":"SJ Kessels","year":"2012","unstructured":"Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 2012; 30(24):3546\u201356.","journal-title":"Vaccine"},{"key":"4108_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.vaccine.2012.05.039","volume":"30","author":"LE Markowitz","year":"2012","unstructured":"Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton J. Human papillomavirus vaccine introduction\u2013the first five years. Vaccine. 2012; 30:139\u201348.","journal-title":"Vaccine"},{"issue":"3","key":"4108_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jnci\/djs491","volume":"105","author":"A Jemal","year":"2013","unstructured":"Jemal A, Simard EP, Dorell C, Noone A-M, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, et al.Annual report to the nation on the status of cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus (HPV)\u2013associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013; 105(3):175\u2013201.","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"4108_CR15","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1016\/j.vaccine.2014.02.071","volume":"32","author":"T Blakely","year":"2014","unstructured":"Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine. 2014; 32(22):2645\u201356.","journal-title":"Vaccine"},{"issue":"8","key":"4108_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2471\/BLT.11.097253","volume":"90","author":"A Binagwaho","year":"2012","unstructured":"Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in rwanda\u2019s national human papillomavirus vaccination programme. Bull World Health Organ. 2012; 90(8):623\u20138.","journal-title":"Bull World Health Organ"},{"issue":"31","key":"4108_CR17","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1016\/j.vaccine.2015.05.078","volume":"33","author":"T Dorji","year":"2015","unstructured":"Dorji T, Tshomo U, Phuntsho S, Tamang TD, Tshokey T, Baussano I, Franceschi S, Clifford G. Introduction of a national HPV vaccination program into Bhutan. Vaccine. 2015; 33(31):3726\u201330.","journal-title":"Vaccine"},{"issue":"3","key":"4108_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","volume":"96","author":"K French","year":"2007","unstructured":"French K, Barnabas R, Lehtinen M, Kontula O, Pukkala E, Dillner J, Garnett G. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age-and sex-specific pattern of vaccination in Finland. Br J Cancer. 2007; 96(3):514\u20138.","journal-title":"Br J Cancer"},{"key":"4108_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/bmj.a769","volume":"337","author":"M Jit","year":"2008","unstructured":"Jit M, Choi YH, Edmunds W. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008; 337:769.","journal-title":"BMJ"},{"issue":"1","key":"4108_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","volume":"11","author":"B Donovan","year":"2011","unstructured":"Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011; 11(1):39\u201344.","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"4108_CR21","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1016\/j.vaccine.2010.02.098","volume":"28","author":"AM Hong","year":"2010","unstructured":"Hong AM, Grulich AE, Jones D, Lee CS, Garland SM, Dobbins TA, Clark JR, Harnett GB, Milross CG, O\u2019Brien CJ, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine. 2010; 28(19):3269\u201372.","journal-title":"Vaccine"},{"key":"4108_CR22","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1136\/bmj.d5775","volume":"343","author":"M Jit","year":"2011","unstructured":"Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011; 343:5775.","journal-title":"BMJ"},{"issue":"1","key":"4108_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/jech-2013-202620","volume":"68","author":"K Sinka","year":"2014","unstructured":"Sinka K, Kavanagh K, Gordon R, Love J, Potts A, Donaghy M, Robertson C. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health. 2014; 68(1):57\u201363.","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"4108_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/infdis\/jiu413","volume":"211","author":"EA Burger","year":"2014","unstructured":"Burger EA, Sy S, Nyg\u00e5rd M, Kristiansen IS, Kim JJ. Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway. J Infect Dis. 2014; 211(2):206\u201315.","journal-title":"J Infect Dis"},{"issue":"4","key":"4108_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1473-3099(07)70083-X","volume":"7","author":"AT Newall","year":"2007","unstructured":"Newall AT, Beutels P, Wood JG, Edmunds W, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007; 7(4):289\u201396.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"4108_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3201\/eid1011.040222","volume":"10","author":"AV Taira","year":"2004","unstructured":"Taira AV, Neukermans CP, Sanders GD, et al. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004; 10(11):1915\u201323.","journal-title":"Emerg Infect Dis"},{"issue":"19","key":"4108_CR27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/jnci\/djr319","volume":"103","author":"AR Kreimer","year":"2011","unstructured":"Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonz\u00e1lez P, Solomon D, Jim\u00e9nez S, Schiller JT, et al.Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine. J Natl Cancer Inst. 2011; 103(19):1444\u201351.","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"4108_CR28","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1001\/jama.2013.1625","volume":"309","author":"SR Dobson","year":"2013","unstructured":"Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al.Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013; 309(17):1793\u2013802.","journal-title":"JAMA"},{"key":"4108_CR29","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.1136\/bmj.g7584","volume":"350","author":"M Jit","year":"2015","unstructured":"Jit M, Brisson M, Laprise J-F, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ. 2015; 350:7584.","journal-title":"BMJ"},{"issue":"5","key":"4108_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1056\/NEJMoa0909537","volume":"364","author":"AR Giuliano","year":"2011","unstructured":"Giuliano AR, Palefsky JM, Goldstone S, Moreira Jr ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011; 364(5):401\u201311.","journal-title":"N Engl J Med"},{"issue":"1","key":"4108_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2468-2667(16)30001-9","volume":"1","author":"M Brisson","year":"2016","unstructured":"Brisson M, B\u00e9nard \u00c9, Drolet M, Bogaards JA, Baussano I, V\u00e4nsk\u00e4 S, Jit M, Boily M-C, Smith M, Berkhof J, et al.Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016; 1(1):8\u201317.","journal-title":"Lancet Public Health"},{"issue":"6","key":"4108_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1086\/323081","volume":"184","author":"L Ahdieh","year":"2001","unstructured":"Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis. 2001; 184(6):682\u201390.","journal-title":"J Infect Dis"},{"issue":"3","key":"4108_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1086\/514082","volume":"176","author":"ME Hagensee","year":"1997","unstructured":"Hagensee ME, Kiviat N, Critchlow CW, Hawes SE, Kuypers J, Holte S, Galloway DA. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis. 1997; 176(3):625\u201331.","journal-title":"J Infect Dis"},{"issue":"1","key":"4108_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/infdis\/jiq021","volume":"203","author":"AG Nyitray","year":"2011","unstructured":"Nyitray AG, da Silva RJC, Baggio ML, Lu B, Smith D, Abrahamsen M, Papenfuss M, Villa LL, Lazcano-Ponce E, Giuliano AR. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis. 2011; 203(1):49\u201357.","journal-title":"J Infect Dis"},{"issue":"9","key":"4108_CR35","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1038\/bjc.2015.90","volume":"112","author":"E King","year":"2015","unstructured":"King E, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Prah P, Jit M, Edmunds W, Sonnenberg P. Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. Br J Cancer. 2015; 112(9):1585\u201393.","journal-title":"Br J Cancer"},{"key":"4108_CR36","doi-asserted-by":"crossref","unstructured":"Matthijsse SM, Hontelez JA, Naber SK, Rozemeijer K, de Kok IM, Bakker R, van Ballegooijen M, van Rosmalen J, de Vlas SJ. Public health benefits of routine human papillomavirus vaccination for adults in the Netherlands: a mathematical modeling study. J Infect Dis. 2016:jiw256.","DOI":"10.1093\/infdis\/jiw256"},{"issue":"33","key":"4108_CR37","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.1016\/j.vaccine.2007.05.058","volume":"25","author":"S Goldie","year":"2007","unstructured":"Goldie S, Kim J, Kobus K, Goldhaber-Fiebert JD, Salomon J, O\u2019Shea MK, Bosch FX, de Sanjos\u00e9 S, Franco E. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007; 25(33):6257\u201370.","journal-title":"Vaccine"},{"issue":"3","key":"4108_CR38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.18553\/jmcp.2010.16.3.217","volume":"16","author":"EP Armstrong","year":"2010","unstructured":"Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010; 16(3):217\u201330.","journal-title":"J Manag Care Pharm"},{"issue":"9","key":"4108_CR39","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/sj.bjc.6604023","volume":"97","author":"J Kim","year":"2007","unstructured":"Kim J, Andres-Beck B, Goldie S. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007; 97(9):1322\u201328.","journal-title":"Br J Cancer"},{"issue":"3","key":"4108_CR40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/infdis\/jir285","volume":"204","author":"M Brisson","year":"2011","unstructured":"Brisson M, van de Velde N, Franco E, Drolet M, Boily M-C. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011; 204(3):372\u20136.","journal-title":"J Infect Dis"},{"key":"4108_CR41","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1136\/bmj.b3884","volume":"339","author":"J Kim","year":"2009","unstructured":"Kim J, Goldie S. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009; 339:3884.","journal-title":"BMJ"},{"issue":"37","key":"4108_CR42","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1016\/j.vaccine.2009.06.039","volume":"27","author":"I Zechmeister","year":"2009","unstructured":"Zechmeister I, de Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009; 27(37):5133\u201341.","journal-title":"Vaccine"},{"issue":"1","key":"4108_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/1471-2334-14-351","volume":"14","author":"AL Pearson","year":"2014","unstructured":"Pearson AL, Kvizhinadze G, Wilson N, Smith M, Canfell K, Blakely T. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. BMC Infect Dis. 2014; 14(1):351.","journal-title":"BMC Infect Dis"},{"issue":"46","key":"4108_CR44","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","volume":"29","author":"HW Chesson","year":"2011","unstructured":"Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011; 29(46):8443\u201350.","journal-title":"Vaccine"},{"issue":"48","key":"4108_CR45","doi-asserted-by":"publisher","first-page":"9112","DOI":"10.1016\/j.vaccine.2011.02.091","volume":"29","author":"M Smith","year":"2011","unstructured":"Smith M, Lew J-B, Walker RJ, Brotherton J, Nickson C, Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine. 2011; 29(48):9112\u201322.","journal-title":"Vaccine"},{"issue":"8","key":"4108_CR46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1473-3099(12)70031-2","volume":"12","author":"M Georgousakis","year":"2012","unstructured":"Georgousakis M, Jayasinghe S, Brotherton J, Gilroy N, Chiu C, Macartney K. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis. 2012; 12(8):627\u201334.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"4108_CR47","first-page":"580","volume":"64","author":"A Lin","year":"2016","unstructured":"Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds W, Sonnenberg P, Gilson R, Bains I, Choi YH, et al. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis. 2016; 64(5):580\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4108_CR48","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-06-0997","volume":"16","author":"CM Nielson","year":"2007","unstructured":"Nielson CM, Flores R, Harris RB, Abrahamsen M, Papenfuss M, Dunne EF, Markowitz LE, Giuliano AR. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomark Prev. 2007; 16(6):1107\u201314.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4108_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pvr.2017.01.001","volume":"3","author":"C Tanton","year":"2017","unstructured":"Tanton C, Mesher D, Beddows S, Soldan K, Clifton S, Panwar K, Field N, Mercer CH, Johnson AM, Sonnenberg P. Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017; 3:36\u201341.","journal-title":"Papillomavirus Res"},{"issue":"11","key":"4108_CR50","first-page":"0206501","volume":"13","author":"S Datta","year":"2018","unstructured":"Datta S, Mercer CH, Keeling MJ. Capturing sexual contact patterns in modelling the spread of sexually transmitted infections: Evidence using Natsal-3. PloS ONE. 2018; 13(11):0206501.","journal-title":"PloS ONE"},{"issue":"7","key":"4108_CR51","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/infdis\/jit615","volume":"209","author":"AG Nyitray","year":"2013","unstructured":"Nyitray AG, Lin H-Y, Fulp WJ, Chang M, Menezes L, Lu B, Abrahamsen M, Papenfuss M, Gage C, Galindo CM, et al.The role of monogamy and duration of heterosexual relationships on human papillomavirus (HPV) transmission. J Infect Dis. 2013; 209(7):1007\u201315.","journal-title":"J Infect Dis"},{"issue":"5","key":"4108_CR52","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/infdis\/174.5.927","volume":"174","author":"JJ Carter","year":"1996","unstructured":"Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee S-K, Kuypers J, Kiviat N, Galloway DA. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996; 174(5):927\u201336.","journal-title":"J Infect Dis"},{"issue":"2","key":"4108_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/infdis\/jir242","volume":"204","author":"ZR Edelstein","year":"2011","unstructured":"Edelstein ZR, Carter JJ, Garg R, Winer R, Feng Q, Galloway DA, Koutsky LA. Serum antibody response following genital \u03b19 human papillomavirus infection in young men. J Infect Dis. 2011; 204(2):209\u201316.","journal-title":"J Infect Dis"},{"key":"4108_CR54","volume-title":"Human Papillomavirus (HPV) vaccination coverage in adolescent females in England: 2014\/15","author":"Public Health England","year":"2015","unstructured":"Public Health England. Human Papillomavirus (HPV) vaccination coverage in adolescent females in England: 2014\/15. London: Public Health England; 2015."},{"issue":"22","key":"4108_CR55","first-page":"4","volume":"10","author":"Public Health England","year":"2016","unstructured":"Public Health England. Infection report. Health Prot Report. 2016; 10(22):4\u20136.","journal-title":"Health Prot Report"},{"issue":"12","key":"4108_CR56","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/archotol.1995.01890120044008","volume":"121","author":"CS Derkay","year":"1995","unstructured":"Derkay CS. Task force on recurrent respiratory papillomas: a preliminary report. Arch Otolaryngol\u2013Head Neck Surg. 1995; 121(12):1386\u201391.","journal-title":"Arch Otolaryngol\u2013Head Neck Surg"},{"issue":"3","key":"4108_CR57","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ijc.22527","volume":"121","author":"JS Smith","year":"2007","unstructured":"Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121(3):621\u201332.","journal-title":"Int J Cancer"},{"key":"4108_CR58","volume-title":"Deaths Registered in England and Wales: 2014","author":"Office of National Statistics","year":"2014","unstructured":"Office of National Statistics. Deaths Registered in England and Wales: 2014. London: Office for National Statistics; 2014."},{"key":"4108_CR59","volume-title":"Cancer registration statistics, England, 2012","author":"Office of National Statistics","year":"2012","unstructured":"Office of National Statistics. Cancer registration statistics, England, 2012. London: Office for National Statistics; 2012."},{"key":"4108_CR60","volume-title":"Cancer survival in England, adults diagnosed 2008-2012 and followed up to 2013","author":"Office of National Statistics","year":"2014","unstructured":"Office of National Statistics. Cancer survival in England, adults diagnosed 2008-2012 and followed up to 2013. London: Office for National Statistics; 2014."},{"issue":"10","key":"4108_CR61","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.ejca.2006.01.019","volume":"42","author":"M Jeffreys","year":"2006","unstructured":"Jeffreys M, Rachet B, McDowell S, Habib AG, Lepage C, Coleman MP. Survival from rectal and anal cancers in England and Wales, 1986-2001. European Journal of Cancer. 2006; 42(10):1434\u201340.","journal-title":"European Journal of Cancer"},{"key":"4108_CR62","volume-title":"One and five year survival of patients diagnosed in 1991-95 and 1996-99: less common cancers, sex and age, England and Wales","author":"Office of National Statistics","year":"2005","unstructured":"Office of National Statistics. One and five year survival of patients diagnosed in 1991-95 and 1996-99: less common cancers, sex and age, England and Wales. London: Office for National Statistics; 2005."},{"issue":"8","key":"4108_CR63","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/archotol.126.8.935","volume":"126","author":"D Bishai","year":"2000","unstructured":"Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol\u2013Head Neck Surg. 2000; 126(8):935\u20139.","journal-title":"Arch Otolaryngol\u2013Head Neck Surg"},{"issue":"8","key":"4108_CR64","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jnci\/djt053","volume":"105","author":"D Anantharaman","year":"2013","unstructured":"Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, Gaborieau V, Marron M, Lagiou P, Ahrens W, et al. Human papillomavirus infections and upper aero-digestive tract cancers: the arcage study. J Natl Cancer Inst. 2013; 105(8):536\u201345.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"4108_CR65","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/ijc.30608","volume":"140","author":"D Anantharaman","year":"2017","unstructured":"Anantharaman D, Abedi-Ardekani B, Beachler DC, Gheit T, Olshan AF, Wisniewski K, Wunsch-Filho V, Toporcov TN, Tajara EH, Levi JE, et al. Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. Int J Cancer. 2017; 140(9):1968\u201375.","journal-title":"Int J Cancer"},{"issue":"6","key":"4108_CR66","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/sextrans-2011-050073","volume":"87","author":"SC Woodhall","year":"2011","unstructured":"Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, Ross JD, Lacey CJN. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011; 87(6):458\u201363.","journal-title":"Sex Transm Infect"},{"issue":"6","key":"4108_CR67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1258\/ijsa.2010.010073","volume":"21","author":"A Donne","year":"2010","unstructured":"Donne A, Clarke R. Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children. Int J STD AIDS. 2010; 21(6):381\u20135.","journal-title":"Int J STD AIDS"},{"issue":"3","key":"4108_CR68","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1258\/ijsa.2011.011218","volume":"23","author":"T Lanitis","year":"2012","unstructured":"Lanitis T, Carroll S, O\u2019Mahony C, Charman F, Khalid J, Griffiths V, Brown R. The cost of managing genital warts in the UK. Int J STD AIDS. 2012; 23(3):189\u201394.","journal-title":"Int J STD AIDS"},{"issue":"12","key":"4108_CR69","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/S0959-8049(98)00232-9","volume":"34","author":"J Wolstenholme","year":"1998","unstructured":"Wolstenholme J, Whynes D. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer. 1998; 34(12):1889\u201393.","journal-title":"Eur J Cancer"},{"key":"4108_CR70","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Clinical Excellence","year":"2013","unstructured":"National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence; 2013. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/technology-appraisal-processes-guide-apr-2018.pdf ."},{"key":"4108_CR71","volume-title":"Cost-Effectiveness Methodology for Immunisation Programmes and Procurements (CEMIPP)","author":"Review of cost-effectiveness methodology for immunisation programmes and procurements","year":"2016","unstructured":"Review of cost-effectiveness methodology for immunisation programmes and procurements. Cost-Effectiveness Methodology for Immunisation Programmes and Procurements (CEMIPP). London: Department of Health; 2016."},{"issue":"04","key":"4108_CR72","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/S0266462311000481","volume":"27","author":"S Staniszewska","year":"2011","unstructured":"Staniszewska S, Brett J, Mockford C, Barber R. The gripp checklist: strengthening the quality of patient and public involvement reporting in research. Int J Technol Assess Health Care. 2011; 27(04):391\u20139.","journal-title":"Int J Technol Assess Health Care"},{"issue":"38","key":"4108_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hsdr03380","volume":"3","author":"P Wilson","year":"2015","unstructured":"Wilson P, Mathie E, Keenan J, McNeilly E, Goodman C, Howe A, Poland F, Staniszewska S, Kendall S, Munday D, et al.ReseArch with Patient and Public invOlvement: a RealisT evaluation\u2013the RAPPORT study. Health Serv Deliv Res. 2015; 3(38):1\u2013208. https:\/\/doi.org\/10.3310\/hsdr03380 .","journal-title":"Health Serv Deliv Res"},{"issue":"9907","key":"4108_CR74","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/S0140-6736(13)62035-8","volume":"382","author":"CH Mercer","year":"2013","unstructured":"Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, Macdowall W, Lewis R, Field N, Datta J, et al.Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet. 2013; 382(9907):1781\u201394.","journal-title":"Lancet"},{"issue":"5","key":"4108_CR75","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1371\/journal.pmed.0030138","volume":"3","author":"R Barnabas","year":"2006","unstructured":"Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G. Epidemiology of HPV 16 and cervical cancer in finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006; 3(5):138.","journal-title":"PLoS Med"},{"issue":"8","key":"4108_CR76","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/ijc.23633","volume":"123","author":"M Smith","year":"2008","unstructured":"Smith M, Canfell K, Brotherton J, Lew J-B, Barnabas R. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer. 2008; 123(8):1854\u201363.","journal-title":"Int J Cancer"},{"issue":"5","key":"4108_CR77","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/aje\/kwu159","volume":"180","author":"NG Campos","year":"2014","unstructured":"Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, Hildesheim A, Herrero R, Kim JJ. An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol. 2014; 180(5):545\u201355.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"4108_CR78","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.vaccine.2013.10.085","volume":"32","author":"D Mesher","year":"2013","unstructured":"Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, Beddows S, Gill O. Reduction in HPV 16\/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013; 32(1):26\u201332.","journal-title":"Vaccine"},{"issue":"9907","key":"4108_CR79","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(13)61947-9","volume":"382","author":"P Sonnenberg","year":"2013","unstructured":"Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, Mercer CH, da Silva FC, Alexander S, Copas AJ, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet. 2013; 382(9907):1795\u2013806.","journal-title":"Lancet"},{"issue":"5","key":"4108_CR80","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","volume":"15","author":"M Drolet","year":"2015","unstructured":"Drolet M, B\u00e9nard \u00c9, Boily M-C, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton J, Cummings T, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15(5):565\u201380.","journal-title":"Lancet Infect Dis"},{"issue":"41","key":"4108_CR81","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1016\/j.vaccine.2008.07.041","volume":"26","author":"J Ryding","year":"2008","unstructured":"Ryding J, French K, Naucler P, Barnabas R, Garnett G, Dillner J. Seroepidemiology as basis for design of a human papillomavirus vaccination program. Vaccine. 2008; 26(41):5263\u20138.","journal-title":"Vaccine"},{"issue":"9","key":"4108_CR82","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","volume":"213","author":"DC Beachler","year":"2016","unstructured":"Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016; 213(9):1444\u201354.","journal-title":"J Infect Dis"},{"key":"4108_CR83","unstructured":"Joint Committee on Vaccination and Immunisation. Statement on HPV vaccination. 2018. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/726319\/JCVI_Statement_on_HPV_vaccination_2018.pdf . Accessed 22 Oct 2018."},{"issue":"9","key":"4108_CR84","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/infdis\/jit360","volume":"208","author":"A Szarewski","year":"2013","unstructured":"Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow S-N, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, et al.Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013; 208(9):1391\u20136.","journal-title":"J Infect Dis"},{"issue":"2","key":"4108_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/infdis\/jiv368","volume":"213","author":"KM Elfstr\u00f6m","year":"2015","unstructured":"Elfstr\u00f6m KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. J Infect Dis. 2015; 213(2):199\u2013205.","journal-title":"J Infect Dis"},{"key":"4108_CR86","unstructured":"Colucci R, Hryniuk W, Savage C. HPV vaccination programs in Canada; Are we hitting the mark? 2008. http:\/\/www.canceradvocacy.ca\/reportcard\/2008\/HPV\u066a20Vaccination\u066a20Programs\u066a20in\u066a20Canada.pdf . Accessed 7 Nov 2017."},{"key":"4108_CR87","unstructured":"Canadian Partnership Against Cancer. The 2016 Cancer System Performance Report. 2016. https:\/\/www.systemperformance.ca\/report\/2016-cancer-system-performance-report\/ . Accessed 25 Nov 2018."},{"issue":"2","key":"4108_CR88","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/infdis\/jix272","volume":"216","author":"V Qendri","year":"2017","unstructured":"Qendri V, Bogaards JA, Berkhof J. Health and economic impact of a tender-based, sex-neutral human papillomavirus 16\/18 vaccination program in the Netherlands. J Infect Dis. 2017; 216(2):210\u20139.","journal-title":"J Infect Dis"},{"issue":"32","key":"4108_CR89","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1016\/j.vaccine.2011.05.018","volume":"29","author":"I Borget","year":"2011","unstructured":"Borget I, Abramowitz L, Mathevet P. Economic burden of HPV-related cancers in france. Vaccine. 2011; 29(32):5245\u20139.","journal-title":"Vaccine"},{"issue":"1","key":"4108_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-10","volume":"13","author":"R Marty","year":"2013","unstructured":"Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer. 2013; 13(1):1.","journal-title":"BMC Cancer"},{"issue":"7","key":"4108_CR91","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/sti.2007.026377","volume":"83","author":"CH Mercer","year":"2007","unstructured":"Mercer CH, Fenton KA, Wellings K, Copas AJ, Erens B, Johnson AM. Sex partner acquisition while overseas: results from a British national probability survey. Sex Transm Infect. 2007; 83(7):517\u201322.","journal-title":"Sex Transm Infect"},{"issue":"9916","key":"4108_CR92","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, et al.Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four european randomised controlled trials. Lancet. 2014; 383(9916):524\u201332.","journal-title":"Lancet"},{"issue":"2","key":"4108_CR93","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/0969141316654197","volume":"24","author":"A Castanon","year":"2017","unstructured":"Castanon A, Landy R, Sasieni P. By how much could screening by primary human papillomavirus testing reduce cervical cancer incidence in England?J Med Screen. 2017; 24(2):110\u20132.","journal-title":"J Med Screen"},{"issue":"4","key":"4108_CR94","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ijc.31094","volume":"142","author":"R Landy","year":"2018","unstructured":"Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? a simulation study. Int J Cancer. 2018; 142(4):709\u201318.","journal-title":"Int J Cancer"},{"issue":"1","key":"4108_CR95","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2468-2667(18)30183-X","volume":"4","author":"MT Hall","year":"2019","unstructured":"Hall MT, Simms KT, Lew J-B, Smith M, Brotherton J, Saville M, Frazer IH, Canfell K. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019; 4(1):19\u201327.","journal-title":"Lancet Public Health"},{"issue":"7","key":"4108_CR96","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/OLQ.0b013e31820bc880","volume":"38","author":"S Desai","year":"2011","unstructured":"Desai S, Chapman R, Jit M, Nichols T, Borrow R, Wilding M, Linford C, Lowndes CM, Nardone A, Pebody R, et al. Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis. 2011; 38(7):622\u20139.","journal-title":"Sex Transm Dis"},{"issue":"2","key":"4108_CR97","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.vaccine.2012.10.087","volume":"31","author":"M Mollers","year":"2013","unstructured":"Mollers M, Hein JB, Henrike JV, Audrey JK, van den Broek Ingrid V, van Bergen Jan E, Antoinette AB, Petra FW, Christian JH, Chris JM, et al. Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands. Vaccine. 2013; 31(2):394\u2013401.","journal-title":"Vaccine"},{"issue":"5","key":"4108_CR98","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1055-9965.EPI-14-1333","volume":"24","author":"C Tanton","year":"2015","unstructured":"Tanton C, Soldan K, Beddows S, Mercer CH, Waller J, Field N, Clifton S, Copas AJ, Panwar K, Manyenga P, et al.High-risk human papillomavirus (HPV) infection and cervical cancer prevention in Britain: Evidence of differential uptake of interventions from a probability survey. Cancer Epidemiol Prev Biomark. 2015; 24(5):842\u201353.","journal-title":"Cancer Epidemiol Prev Biomark"},{"issue":"13","key":"4108_CR99","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.vaccine.2013.01.026","volume":"31","author":"T Malag\u00f3n","year":"2013","unstructured":"Malag\u00f3n T, Joumier V, Boily M-C, Van de Velde N, Drolet M, Brisson M. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis. Vaccine. 2013; 31(13):1740\u20137.","journal-title":"Vaccine"},{"issue":"4","key":"4108_CR100","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1158\/1055-9965.EPI-12-1173","volume":"22","author":"M Drolet","year":"2013","unstructured":"Drolet M, Boily M-C, Greenaway C, Deeks SL, Blanchette C, Laprise J-F, Brisson M. Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination. Cancer Epidemiol Biomark Prev. 2013; 22(4):641\u201352.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"4108_CR101","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/sextrans-2013-051179","volume":"90","author":"RJ Sacks","year":"2014","unstructured":"Sacks RJ, Copas AJ, Wilkinson DM, Robinson AJ. Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services. Sex Transm Infect. 2014; 90(4):315\u201321.","journal-title":"Sex Transm Infect"},{"issue":"4","key":"4108_CR102","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jcv.2003.09.016","volume":"29","author":"S Hahn\u00e9","year":"2004","unstructured":"Hahn\u00e9 S, Ramsay M, Balogun K, Edmunds W, Mortimer P. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995\u20132000: implications for immunisation policy. J Clin Virol. 2004; 29(4):211\u201320.","journal-title":"J Clin Virol"},{"issue":"7","key":"4108_CR103","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrclinonc.2013.84","volume":"10","author":"M Lehtinen","year":"2013","unstructured":"Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 2013; 10(7):400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4108_CR104","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/ijc.27828","volume":"133","author":"AF Rositch","year":"2013","unstructured":"Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco E, Poole C, Smith JS. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer. 2013; 133(6):1271\u201385.","journal-title":"Int J Cancer"},{"issue":"9296","key":"4108_CR105","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(01)06883-0","volume":"358","author":"AM Johnson","year":"2001","unstructured":"Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S, Wellings K, Fenton KA, Korovessis C, Macdowall W, Nanchahal K, et al. Sexual behaviour in Britain: partnerships, practices, and hiv risk behaviours. Lancet. 2001; 358(9296):1835\u201342.","journal-title":"Lancet"},{"issue":"9907","key":"4108_CR106","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/S0140-6736(13)62378-8","volume":"382","author":"K Wellings","year":"2013","unstructured":"Wellings K, Johnson AM. Framing sexual health research: adopting a broader perspective. Lancet. 2013; 382(9907):1759\u201362.","journal-title":"Lancet"},{"key":"4108_CR107","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.epidem.2018.05.003","volume":"25","author":"T Leng","year":"2018","unstructured":"Leng T, Keeling MJ. Concurrency of partnerships, consistency with data, and control of sexually transmitted infections. Epidemics. 2018; 25:35\u201346.","journal-title":"Epidemics"},{"issue":"37","key":"4108_CR108","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1016\/j.vaccine.2013.06.064","volume":"31","author":"M Brisson","year":"2013","unstructured":"Brisson M, Laprise J-F, Drolet M, Van de Velde N, Franco E, Kliewer EV, Ogilvie G, Deeks SL, Boily M-C. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine. 2013; 31(37):3863\u201371.","journal-title":"Vaccine"},{"issue":"6","key":"4108_CR109","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/sextrans-2013-051490","volume":"90","author":"CE Introcaso","year":"2014","unstructured":"Introcaso CE, Dunne EF, Hariri S, Panicker G, Unger ER, Markowitz LE. Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the USA, National Health and Nutrition Examination Surveys, 2003\u20132006. Sex Transm Infect. 2014; 90(6):505\u20138.","journal-title":"Sex Transm Infect"},{"issue":"3","key":"4108_CR110","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/OLQ.0b013e31815abaef","volume":"35","author":"S Hariri","year":"2008","unstructured":"Hariri S, Dunne EF, Sternberg M, Unger ER, Meadows KS, Karem KL, Markowitz LE. Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health And Nutrition Examination Survey, 1991\u20131994. Sex Transm Dis. 2008; 35(3):298\u2013303.","journal-title":"Sex Transm Dis"},{"issue":"10","key":"4108_CR111","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1086\/344354","volume":"186","author":"KM Stone","year":"2002","unstructured":"Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002; 186(10):1396\u2013402.","journal-title":"J Infect Dis"},{"issue":"7","key":"4108_CR112","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.bjc.6603955","volume":"97","author":"M Jit","year":"2007","unstructured":"Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer. 2007; 97(7):989\u201391.","journal-title":"Br J Cancer"},{"issue":"1","key":"4108_CR113","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/1471-2334-14-361","volume":"14","author":"FA Castro","year":"2014","unstructured":"Castro FA, Dominguez A, Puschel K, Van De Wyngard V, Snijders PJ, Franceschi S, Pawlita M, Ferreccio C. Serological prevalence and persistence of high-risk human papilloma infection among women in Santiago, Chile. BMC Infect Dis. 2014; 14(1):361.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"4108_CR114","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/sj.bjc.6604324","volume":"98","author":"A Sargent","year":"2008","unstructured":"Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008; 98(10):1704\u20139.","journal-title":"Br J Cancer"},{"issue":"6","key":"4108_CR115","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1086\/591095","volume":"198","author":"AR Giuliano","year":"2008","unstructured":"Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss M, Lee J-H, Abrahamsen M, Harris RB. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis. 2008; 198(6):827\u201335.","journal-title":"J Infect Dis"},{"issue":"1","key":"4108_CR116","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/1471-2334-13-519","volume":"13","author":"K Kavanagh","year":"2013","unstructured":"Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, Cubie H, Donaghy M, Robertson C. Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis. 2013; 13(1):519.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"4108_CR117","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1185\/030079906X99972","volume":"22","author":"R Brown","year":"2006","unstructured":"Brown R, Breugelmans J, Theodoratou D, Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin. 2006; 22(4):663\u201370.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"4108_CR118","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","volume":"36","author":"MR Gold","year":"1998","unstructured":"Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998; 36(6):778\u201392.","journal-title":"Med Care"},{"issue":"10","key":"4108_CR119","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.ijom.2006.07.017","volume":"35","author":"S Rogers","year":"2006","unstructured":"Rogers S, Miller R, Ali K, Minhas A, Williams H, Lowe D. Patients\u2019 perceived health status following primary surgery for oral and oropharyngeal cancer. Int J Oral Maxillofac Surg. 2006; 35(10):913\u20139.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"4","key":"4108_CR120","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/0272989X07302128","volume":"27","author":"RP Insinga","year":"2007","unstructured":"Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Dec Making. 2007; 27(4):414\u201322.","journal-title":"Med Dec Making"},{"issue":"5","key":"4108_CR121","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.ijrobp.2008.06.1905","volume":"73","author":"IJ Korfage","year":"2009","unstructured":"Korfage IJ, Essink-Bot M-L, Mols F, van de Poll-Franse L, Kruitwagen R, van Ballegooijen M. Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol* Biol* Phys. 2009; 73(5):1501\u20139.","journal-title":"Int J Radiat Oncol* Biol* Phys"},{"issue":"21","key":"4108_CR122","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1158\/0008-5472.CAN-10-0621","volume":"70","author":"H Trottier","year":"2010","unstructured":"Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JCM, Rohan TE, Villa LL, Franco E. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010; 70(21):8569\u201377.","journal-title":"Cancer Res"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4108-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T11:10:32Z","timestamp":1610017832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4108-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4108"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4108-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]},"assertion":[{"value":"23 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. MU is Chief Investigator or co-applicant on multiple research projects funded by NIHR, and a journal editor for NIHR for which he receives a fee; MU is director and shareholder of Clinvivo Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"552"}}